NAMS | NewAmsterdam Pharma Company N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	24.55 - 26.25
52 Week Range	10.50 - 27.29
Beta	1.22
Implied Volatility	60.33%
IV Rank	5.54%
Day's Volume	1,004,960
Average Volume	723,166
Shares Outstanding	106,832,951
Market Cap	2,724,240,251
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-09

Valuation
Profitability
Growth
Health
P/E Ratio	-11.54
Forward P/E Ratio	N/A
EPS	-2.21
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	62
Country	Netherlands
Website	NAMS

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NAMS's peers: CLGN, CMPX, GANX, GNLX, IMRX, IOBT, IVA, MIST, NVCT, REPL, RLMD, PMN, NAMSW, GLUE, CGEM, CRNX, PRTC, MRUS, MLYS, ELYM, ANEB, JANX, RZLT, MOLN, PEPG, CYT

*Chart delayed

Analyzing fundamentals for NAMS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see NAMS Fundamentals page.

Watching at NAMS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NAMS Technicals page.